Trials / Completed
CompletedNCT03289182
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
Post-Marketing Surveillance of MabThera Subcutaneous in Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 701 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multicenter, non-interventional study to test the safety and effectiveness of MabThera administered subcutaneously in participants with NHL or CLL. The length of study is expected to be 6 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MabThera | Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling. |
Timeline
- Start date
- 2017-09-15
- Primary completion
- 2020-10-27
- Completion
- 2020-10-27
- First posted
- 2017-09-20
- Last updated
- 2021-01-11
Locations
25 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03289182. Inclusion in this directory is not an endorsement.